Aequus Pharmaceuticals Inc (CVE:AQS) (OCTMKTS:AQSZF) on Thursday unveiled positive news on its tacrolimus drug in British Columbia, which is used to prevent patient rejection after organ transplants.
As of November 4, 2019, a major health authority mandated that the drug Sandoz tacrolimus is to be dispensed to all new patients requiring tacrolimus for prophylaxis in the province, the pharma group said in a statement.
Aequus receives a revenue share of the product from its partner Sandoz.
"This is great news from our home province,” Doug Janzen, the chief executive of Aequus, told investors.
"Our commercial and market access teams have worked hard to provide the province with an alternative to the branded product, Prograf, which currently sells roughly $20M in product annually in British Columbia.
"This access will provide an added boost to our already impressive performance of growing Sandoz tacrolimus revenues across Canada and is the second piece of positive reimbursement news that Aequus has had regarding its growing product portfolio so far in 2020."
Between 2011 and 2018, British Columbia conducted 2,750 heart, kidney, or liver transplants.
As of 2018, 4,870 people living with organ transplantation resided in British Columbia, representing around 20% of transplant patients in Canada.
A first line calcineurin inhibitor treatment
Tacrolimus is recommended as a first-line calcineurin inhibitor treatment by the British Columbia transplant consensus guidelines and is prescribed in over 90% of new kidney transplant patients.
Earlier this month, Aequus said it had advanced filings for provincial reimbursement in Quebec and British Columbia for its flagship glaucoma-treatment product Vistitan.
If successful, the additional coverage would advance sales in the second and third largest markets in Canada and would trigger an increase in the percentage of total revenue that Aequus receives from its partner.
Contact the author at [email protected]